Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$41.22 USD

41.22
2,409,519

+0.04 (0.10%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $41.20 -0.02 (-0.05%) 6:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data

by Zacks Equity Research

Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.

SpringWorks (SWTX) Begins Dosing in Multiple Myeloma Study

by Zacks Equity Research

SpringWorks (SWTX) doses the first patient in a phase Ib study evaluating nirogacestat in combination with teclistamab for the treatment of relapsed or refractory multiple myeloma.

Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More

by Zacks Equity Research

The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.

Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL (Revised)

by Zacks Equity Research

FDA issues a complete response letter to Merck's (MRK) sBLA seeking label expansion of Keytruda as neoadjuvant and adjuvant treatment for patients with triple-negative breast cancer. A phase III study in this indication is ongoing.

Merck (MRK) Keytruda Gets CHMP Nod for First-Line Bladder Cancer

by Zacks Equity Research

Merck (MRK) is seeking approval for label expansion of Keytruda in Europe to include first-line treatment of certain patients with advanced or metastatic urothelial carcinoma.

Akebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKD

by Zacks Equity Research

Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis.

Novartis (NVS) Gets EC Nod For Kesimpta in Relapsing Forms of MS

by Zacks Equity Research

The European Commission approves Novartis' (NVS) Kesimpta for the treatment of adult patients with relapsing forms of multiple sclerosis.

Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL

by Zacks Equity Research

FDA issues a complete response letter to Merck's (MRK) sBLA seeking label expansion of Keytruda as neoadjuvant and adjuvant treatment for patients with triple-negative breast cancer. A phase III study in this indication is ongoing.

Lilly/Vir's Cocktail COVID-19 Therapy Meets Study Endpoint

by Zacks Equity Research

Eli Lilly (LLY), Vir Biotechnology and Glaxo are developing a combination of their respective monoclonal antibodies as a potential treatment for mild-to-moderate COVID-19 patients.

Kaleido (KLDO) Reports Positive Results from COVID-19 Study

by Zacks Equity Research

Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.

Regeneron (REGN) Announces Positive Data on COVID-19 Cocktail

by Zacks Equity Research

Regeneron (REGN) announces positive data from a phase III study on its antibody cocktail for COVID-19.

Merck (MRK) Gets FDA Nod for Keytruda in Esophageal Cancer

by Zacks Equity Research

The FDA approves Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy, for the first-line treatment of esophageal and gastroesophageal junction carcinoma.

Glaxo (GSK) Begins Late-Stage Severe Eosinophilic Asthma Study

by Zacks Equity Research

Glaxo (GSK) is developing an anti-IL-5 monoclonal antibody candidate, GSK3511294 - engineered for high affinity and long-acting suppression of IL-5 function - for treating severe asthma patients.

Kinjel Shah headshot

Pharma Stock Roundup: J&J, AZN COVID-19 Update, FDA Delays Decision on ABBV's sNDA

by Kinjel Shah

WHO gives EUL to J&J's (JNJ) COVID-19 vaccine. FDA pushes back review on AbbVie's (ABBV) sNDA

Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More

by Zacks Equity Research

The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.

Gilead (GILD), Merck Collaborate for Long-Acting HIV Treatments

by Zacks Equity Research

Gilead (GILD) collaborates with Merck for developing long-acting treatments for HIV patients.

Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage

by Zacks Equity Research

The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.

Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization Risk

by Zacks Equity Research

Vir Biotechnology (VIR) and partner Glaxo's, antibody candidate, VIR-7831, reduces hospitalization and risk of death in early treatment of adult patients with COVID-19.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod for J&J COVID-19 Vaccine, Updates From LLY, GSK, MRK

by Kinjel Shah

Europe clears J&J's (JNJ) COVID-19 vaccine. Eli Lilly (LLY), Merck (MRK) and Glaxo (GSK) give update on their COVID-19 antibody/antiviral candidates.

GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed at $35.55 in the latest trading session, marking a -0.14% move from the prior day.

Lilly (LLY) COVID-19 Antibody Combo Cuts Death/Hospitalization

by Zacks Equity Research

Lilly's (LLY) combination of its antibody drugs, bamlanivimab and etesevimab cuts death and hospitalizations, per new data from the BLAZE-1 phase III study.

Lilly (LLY) Outperforms Industry Year to Date: Here's Why

by Zacks Equity Research

Lilly's (LLY) shares are up this year mainly due to positive developments related to its antibodies to treat COVID-19 and pipeline.

AnaptysBio (ANAB) Plunges on Lead Candidate Study Failure

by Zacks Equity Research

AnaptysBio's (ANAB) lead pipeline candidate, imsidolimab, fails to meet primary endpoint of a mid-stage study evaluating it in patients with auto-inflammatory disease, palmoplantar pustulosis.

Lilly (LLY) COVID-19 Antibody Bamlanivimab Gets CHMP Nod

by Zacks Equity Research

CHMP recommends approval of Eli Lilly's (LLY) COVID-19 antibody bamlanivimab, alone and in combination with etesevimab in Europe.

Sanofi's (SNY) Dupixent sBLA for Asthma Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Sanofi's (SNY) sBLA for review of Dupixent for treating moderate-to-severe asthma in children aged six-11 years. A verdict from the FDA is expected on Oct 21, 2021.